Grace Therapeutics (NASDAQ:GRCE) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Grace Therapeutics (NASDAQ:GRCE) released its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01, Zacks reports.

Grace Therapeutics Stock Performance

Shares of Grace Therapeutics stock traded up $0.02 during trading on Thursday, hitting $3.50. 14,702 shares of the stock traded hands, compared to its average volume of 126,945. The business has a fifty day simple moving average of $3.74. The company has a market capitalization of $35.49 million, a PE ratio of -3.47 and a beta of 1.36. Grace Therapeutics has a 52 week low of $2.13 and a 52 week high of $4.97.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.